Wegovy
FDA-approved for weight loss. Backed by the largest trials in history.
Wegovy (semaglutide 2.4mg) is the first FDA-approved GLP-1 therapy specifically indicated for chronic weight management in adults with overweight or obesity. At its higher dose of 2.4mg weekly, it delivers the most significant weight loss results of any GLP-1 medication — with clinical trials showing an average of 15–17% body weight reduction.
Key Benefits
- ✓Highest-dose FDA-approved semaglutide for weight loss
- ✓Average 15–17% body weight reduction in trials
- ✓Reduced risk of major cardiovascular events (SELECT trial)
- ✓Improves mobility and physical function
- ✓Significant reduction in waist circumference
- ✓Comprehensive provider support throughout
Quick Facts
Wegovy uses the same semaglutide molecule as Ozempic but at a higher weekly dose (2.4mg vs. 2mg maximum) specifically optimized for weight loss. This higher dose produces more pronounced appetite suppression and a greater reduction in caloric intake. The STEP clinical trial program — the most extensive weight management trials ever conducted — demonstrated not just weight loss but meaningful improvements in physical function, quality of life, and cardiovascular outcomes.
More from Weight Loss
You Might Also Like
All prescription treatments require approval from a licensed healthcare provider. Results may vary. This product has not been evaluated by the FDA for the specific indications described. Reclaimed is a telehealth platform — we facilitate connections between patients and licensed providers, not the practice of medicine directly. Please consult your provider with any questions about your treatment.